Although the 2016 WHO classification of CNS tumors suggested using IDH1 mutation status and chromosome 1p19q codeletion status to stratify LGG patients into clinically distinct subgroups, this classification still remains limited in prognosis predictions. The gene discussed is IDH1; the disease is central nervous system neoplasm.